Home > Poor-quality studies

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Carson S, Lee N, Thakurta S. Drug Class Review: Newer Antihistamines: Final Report Update 2 [Internet]. Portland (OR): Oregon Health & Science University; 2010 May.

Appendix FPoor-quality studies

Original Report and Update 1

Placebo-controlled trials
Bernstein 1997Fexofenadine 60, 120, 240 mg bidSAR, mc, r db, pc, 57 pts late summer 2 wks
Casale 1999Fexofenadine 120 or 180 mg qdSAR mc, r, pc, 861 pts. 2 wks
Ciprandi 2001Fexofenadine 120 180mgPAR, db, pc, 31 pts 4 wks
Dolovich 1994Loratadine 10 mg qdSAR, db, pc, 180 pts 6 weeks
Juhlin 1991Cetirizine 10 or 20 mg qdCIU, db, pc, 30 pts 2 wks
Juhlin 1988Cetirizine 10 mg qdCIU, r, db, pc, 30 pts 2 wks
Mansmann 1991Cetirizine 10, 20 mg qdPAR, db, pc, 215 pts 4 wk
Meltzer 1999Fexofenadine 120 or 180 mg qdSAR, r, db, pc, QoL
Monroe 2003Desloratadine 5mg qdCIU, r, db, pc, 6 wk
Monroe 1998Loratadine 10 mg qdCIU, mc, db, pc, 169 pts. 4 wks
Murray 2002CetirizineSAR mc, r, db, pc, , 865 pts. 2 wks
Nelson 2000Fexofenadine 20, 60, 120, or 240mgCIU, r, db, pc, 4 wks
Raptopoulou 1993Loratadine 10 mgSAR, db, pc, 48 pts. 4 wks
Salmun 2002Desloratadine 2.5, 5, 7.5, 10, or 20 mg qdSAR, r, db, pc, 1026 pts 2 wks
Thompson 2000Fexofenadine 60 mg twice dailyCUI mc, r db, pc 160 & 165 pt trials 4 wks
Vena 2002Fexofenadine 180 mg qdCIU, open, 20 pts. 4 wks.
Wasserman 1991Cetirizine 10 mg and 5mg qdSAR, db, pc, 88 pts spring 2 wks
Zuberbier 1995Cetirizine 10 or 20 mg qdCIU, r, db, 24 pts 3wks
Zuberbier 1996Cetirizine 20 mg qdCIU, db, pc, 11 pts. 3 wks

Abbreviations: bid, twice daily; CIU, chronic idiopathic urticaria; db, double blind; PAR, perennial allergic rhinitis; pts, patients; qd, once daily; QoL, quality-of-life; mc, SAR, seasonal allergic rhinitis; tid; 3 times daily; wks, weeks.

Update 2

Amat P, Novella A, Roma J, Valero A, Lluch M, Malet A. Treatment of perennial allergic rhinitis with cetirizine. Allergol Immunopathol. 1992;20(4):139–143.
Berlin JM, Golden SJ, Teets S, Lehman EB, Lucas T, Craig TJ. Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis. J Am Osteopath Assoc.2000;100(7 Suppl):S8–13.
Bruttmann G, Arendt C, Bernheim J. Double-blind, placebo controlled comparison of cetirizine 2HC1 and terfenadine in atopic perennial rhinitis. Acta Therapeutica.1989;15(1):99–109.
Ciprandi G, Cirillo I, Vizzaccaro A, et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. International Immunopharmacology.2005;5(13–14):1800–1808.
Dorow P, Aurich R, Petzold U. Efficacy and tolerability of azelastine nasal spray in patients with allergic rhinitis compared to placebo and budesonide. Arzneimittelforschung.1993;43(8):909–912.
Hampel FC, Jr., Ratner PH, Amar NJ, et al. Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. Allergy Asthma Proc.2006;27(3):202–207.
Mahmoud F, Arifhodzic N, Haines D, Novotney L. Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis. Journal of Pharmacological Sciences.2008;108(2):149–156.
Potter PC, Paediatric Levocetirizine Study G. Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Ann Allergy Asthma Immunol.2005;95(2):175–180.
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.
Cover of Drug Class Review: Newer Antihistamines
Drug Class Review: Newer Antihistamines: Final Report Update 2 [Internet].
Carson S, Lee N, Thakurta S.
Portland (OR): Oregon Health & Science University; 2010 May.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...